Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedJun 01, 2026
DataAggregated Company Financials
Companies9
  • 7D-1.0%
  • 3M-5.5%
  • 1Y27.1%
  • YTD4.6%

Last week, the Pharma industry hasn't moved much but Galderma Group is up 3.3% in that time. The past year has been better, since the industry has gained 27% in that time. Looking forward, earnings are forecast to grow by 11% annually.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 02 Jun 2026CHF 551.7bCHF 120.9bCHF 24.7b39.8x22.3x4.6x
Thu, 30 Apr 2026CHF 539.5bCHF 121.6bCHF 24.9b36.7x21.7x4.4x
Sat, 28 Mar 2026CHF 544.6bCHF 122.2bCHF 25.4b35.9x21.5x4.5x
Mon, 23 Feb 2026CHF 607.2bCHF 119.7bCHF 24.3b37.2x24.9x5.1x
Wed, 21 Jan 2026CHF 584.3bCHF 120.6bCHF 21.4b36.9x27.3x4.8x
Fri, 19 Dec 2025CHF 550.6bCHF 121.0bCHF 21.5b33.3x25.6x4.6x
Sun, 16 Nov 2025CHF 510.6bCHF 120.9bCHF 21.5b33.4x23.8x4.2x
Tue, 14 Oct 2025CHF 511.5bCHF 120.7bCHF 21.0b33.6x24.3x4.2x
Thu, 11 Sep 2025CHF 484.3bCHF 120.4bCHF 21.0b31.3x23.1x4x
Sat, 09 Aug 2025CHF 449.9bCHF 120.8bCHF 20.9b22.2x21.5x3.7x
Mon, 07 Jul 2025CHF 452.9bCHF 117.1bCHF 18.9b25x24x3.9x
Wed, 04 Jun 2025CHF 447.9bCHF 119.1bCHF 19.3b25.4x23.2x3.8x
Fri, 02 May 2025CHF 441.8bCHF 119.4bCHF 19.3b25.9x22.9x3.7x
Sun, 30 Mar 2025CHF 467.4bCHF 121.7bCHF 19.2b28.5x24.3x3.8x
Tue, 25 Feb 2025CHF 483.2bCHF 122.2bCHF 19.1b23.4x25.3x4x
Thu, 23 Jan 2025CHF 444.3bCHF 119.5bCHF 21.4b18.7x20.8x3.7x
Sat, 21 Dec 2024CHF 415.3bCHF 118.6bCHF 21.2b17.5x19.6x3.5x
Mon, 18 Nov 2024CHF 430.9bCHF 118.3bCHF 21.2b18.4x20.3x3.6x
Wed, 16 Oct 2024CHF 461.1bCHF 115.7bCHF 19.4b21.9x23.7x4x
Fri, 13 Sep 2024CHF 449.4bCHF 115.0bCHF 19.3b21.5x23.2x3.9x
Sun, 11 Aug 2024CHF 456.9bCHF 115.8bCHF 19.5b21.6x23.5x3.9x
Tue, 09 Jul 2024CHF 431.9bCHF 116.3bCHF 19.8b34.2x21.9x3.7x
Thu, 06 Jun 2024CHF 419.3bCHF 116.1bCHF 19.7b44.9x21.2x3.6x
Sat, 04 May 2024CHF 389.1bCHF 113.1bCHF 19.9b39x19.6x3.4x
Mon, 01 Apr 2024CHF 407.1bCHF 112.0bCHF 19.4b38.1x21x3.6x
Wed, 28 Feb 2024CHF 388.1bCHF 110.3bCHF 19.7b24.6x19.7x3.5x
Fri, 26 Jan 2024CHF 409.8bCHF 120.4bCHF 18.8b27x21.8x3.4x
Sun, 24 Dec 2023CHF 394.7bCHF 119.6bCHF 18.7b25x21.1x3.3x
Tue, 21 Nov 2023CHF 387.1bCHF 121.4bCHF 18.9b24x20.4x3.2x
Thu, 19 Oct 2023CHF 404.8bCHF 121.3bCHF 18.6b26.2x21.8x3.3x
Sat, 16 Sep 2023CHF 409.8bCHF 112.6bCHF 18.0b47.1x22.7x3.6x
Mon, 14 Aug 2023CHF 413.3bCHF 111.6bCHF 17.9b48.5x23.1x3.7x
Wed, 12 Jul 2023CHF 404.7bCHF 114.3bCHF 18.8b35.7x21.6x3.5x
Fri, 09 Jun 2023CHF 430.7bCHF 115.4bCHF 18.9b37.7x22.8x3.7x
Price to Earnings Ratio

22.8x


Total Market Cap: CHF 430.7bTotal Earnings: CHF 18.9bTotal Revenue: CHF 115.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 22.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 22.5x.
  • The 3-year average PS ratio of 3.9x is lower than the industry's current PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 9.3% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market0.62%
Healthcare-0.71%
Pharma-0.99%
Pharma-0.99%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GALD Galderma GroupCHF 163.903.3%
+CHF 1.2b		48.1%PE79.7x
CURN Curatis HoldingCHF 24.402.1%
+CHF 2.6m		100.0%PS11.6x
BIOV BioVersysCHF 27.100.4%
+CHF 584.8k		-23.9%PS49.9x

Latest News

NOVN
CHF 113.90
Novartis
7D
-4.7%
1Y
19.8%
ROP
CHF 317.40
Roche Holding
7D
-5.1%
1Y
19.9%
DESN
CHF 301.00
Dottikon ES Holding
7D
-17.1%
1Y
17.1%
SDZ
CHF 64.22
Sandoz Group
7D
-0.3%
1Y
53.7%
Narrative Update • May 28

SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E

Analysts have adjusted the Sandoz Group price target slightly higher, with the updated fair value estimate moving from about CHF 66.01 to CHF 66.36 as they factor in modestly different assumptions for growth, margins and future P/E, following a mix of recent upgrades, initiations and target changes across the Street. Analyst Commentary Recent research on Sandoz Group reflects a mix of optimism and caution, with several firms adjusting ratings and price targets in different directions.
GALD
CHF 163.90
Galderma Group
7D
3.3%
1Y
48.1%
COPN
CHF 75.20
Cosmo
7D
-3.7%
1Y
35.5%
Narrative Update • May 16

Cosmo Pharmaceuticals Will Achieve Its Target Price of €95–110 in 12 Months

Below is a full institutional-style comps + valuation (target price) for Cosmo Pharmaceuticals N.V. , integrating: ✅ FY2025 audited report (your PDF) ✅ Product + pipeline positioning (Cosmo site + report) ✅ Sell-side-style benchmarking framework (SWS-type approach: specialty pharma + medtech AI comps) 1) Investment framing (key drivers) Business mix (unique hybrid) Cosmo is a multi-vertical life sciences platform : MedTech AI (GI Genius™) → high-growth SaaS/MedTech multiple Dermatology (Winlevi + Clascoterone) → specialty pharma growth GI pharma + royalties (MMX platform) → stable cash flows CDMO → low multiple, stabilizer Important: market struggles to value hybrid → mispricing opportunity 2) Financial baseline (FY2025) Core metrics Revenue: €104.2m Recurring revenue: €88.1m (+15%) EBITDA: €9.5m Net income: –€3.5m Cash + investments: €128.3m Market cap: €1.98bn 2025 distorted due to: loss of €186m Medtronic milestone (2024) underlying recurring growth intact (+15%) 3) Product + pipeline valuation bridge A. Commercial assets (anchor value) 1.
NWRN
CHF 13.08
Newron Pharmaceuticals
7D
-6.8%
1Y
79.7%
New Narrative • May 10

Still A Binary Phase III Bet on Evenamide

Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.
BIOV
CHF 27.10
BioVersys
7D
0.4%
1Y
-23.9%
ADXN
CHF 0.045
Addex Therapeutics
7D
-3.8%
1Y
-22.0%
CURN
CHF 24.40
Curatis Holding
7D
2.1%
1Y
100.0%